Dec 27 (Reuters) - Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer. (Reporting by Christy Santhosh; Editing by Shailesh Kuber)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.18 USD | -0.54% | -5.15% | +26.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.94% | 2.87B | |
-31.02% | 9.3B | |
-8.41% | 3.1B | |
-14.31% | 2.17B | |
-19.19% | 1.75B | |
+70.66% | 1.5B | |
+30.00% | 807M | |
-1.97% | 759M | |
-26.63% | 532M | |
+5.17% | 313M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- US FDA places clinical hold on Iovance's lung cancer treatment trial